A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD

CMR Substudy of Coronary Sinus Reducer for the Management of Symptomatic Heart Failure With a Preserved Ejection Fraction (HFpEF) Associated With Coronary Microvascular Dysfunction (CMD)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07093528

Enrollment

Registered

2025-07-30

Start date

2025-10-16

Completion date

2027-08-01

Last updated

2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure With Preserved Ejection Fraction, Coronary Microvascular Dysfunction

Brief summary

To evaluate the effect of CS reducer implantation in patients with HFPEF and CMD on myocardial ischemia, measured by stress myocardial perfusion using cardiovascular magnetic resonance (CMR)

Interventions

DIAGNOSTIC_TESTCardiovascular Magnetic Resonance (CMR)

Patients will consent to undergo a 50-minute non-invasive stress perfusion CMR.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥18 * Enrollment in main CS-reducer HFPEF study IRB# 25-002292

Exclusion criteria

* Metal implants that are not suitable for MRI * Inability or unwillingness of individual to give written informed consent.

Design outcomes

Primary

Measure	Time frame	Description
Change in endocardial:epicardial perfusion ratio	Baseline, 6 Months	Endocardial:Epicardial Perfusion Ratio is a measure of myocardial blood flow and will be determined by Cardiovascular magnetic resonance (CMR)

Countries

United States

Contacts

CONTACTDiana Albers

albers.diana2@mayo.edu507-255-6884

PRINCIPAL_INVESTIGATORClaire Raphael, M.B.B.S., Ph.D.

Mayo Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026